Related Experiment Videos
Intravenous immunoglobulin for Flavobacterium-induced thrombocytopenia in a premature infant
1Department of Pediatrics, Hadassah University Hospital, Jerusalem, Israel.
American Journal of Perinatology
|May 1, 1991
Insights
Intravenous immunoglobulin (IVIG) can prevent serious infections in newborns. This case report shows high-dose IVIG successfully treated Flavobacterium-induced thrombocytopenia in a premature infant.
Area of Science:
- Neonatal Medicine
- Immunology
- Infectious Diseases
Background:
- Gram-negative septicemia poses significant risks, including morbidity and mortality, in neonatal intensive care units.
- Prophylactic administration of intravenous immunoglobulin (IVIG) has demonstrated efficacy in reducing the incidence and severity of infections in infants.
Observation:
- A premature infant developed thrombocytopenia secondary to Flavobacterium infection.
- This condition presented a critical challenge due to the potential for severe complications.
Findings:
- The case report details the successful application of high-dose IVIG in managing this specific clinical scenario.
- Treatment with high-dose IVIG led to a positive clinical outcome for the infant.
Implications:
- High-dose IVIG may be a valuable therapeutic option for Gram-negative septicemia and associated complications like thrombocytopenia in premature infants.
- This case highlights the potential role of immunoglobulins in managing severe infections and hematological disturbances in neonates.
Abstract:
Gram-negative septicemia at times causes morbidity and mortality in newborn nurseries. Prophylactic intravenous immunoglobulin results in a significant decrease in incidence and severity of septicemia resulting from infection in infants. The present case report describes the successful use of high-dose intravenous immunoglobulin in a Flavobacterium-induced thrombocytopenia in a premature infant.